8 completed, 1 active not recruiting. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Fibrous Dysplasia of Bone: new trials by email Literature Review of Fibrous Dysplasia of Bone trials Research Report on Fibrous Dysplasia of Bone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia Burosumab - Fibrous Dysplasia Of Bone | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 12 | 2022-12-07 | 2026-02-02 |
| Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia denosumab - Fibrous Dysplasia | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 15 | 2022-10-12 | 2026-01-20 |
| Denosumab Treatment for Fibrous Dysplasia Denosumab - Bone Diseases, Pain | Phase 2 | Active not recruiting | National Institute of Dental and Craniofacial Research (NIDCR) | 9 | 2019-06-13 | 2022-02-18 |
| TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE Tocilizumab, Placebo - Fibrous Dysplasia of Bone | Phase 2 | Completed | Hospices Civils de Lyon | 19 | 2013-05-05 | 2025-10-02 |
| Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone risedronate, placebo - Fibrous Dysplasia of Bone | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 80 | 2007-07-22 | 2021-08-30 |
| Faslodex in McCune-Albright Syndrome Fulvestrant - Puberty, Precocious, McCune-Albright Syndrome | Phase 2 | Completed | AstraZeneca | 30 | 2006-01-31 | 2024-03-05 |
| Arimidex in McCune Albright Syndrome Arimidex 1 mg - McCune-Albright Syndrome | Phase 2 | Completed | AstraZeneca | 40 | 2002-08-01 | 2015-09-01 |
| Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome Fosamax (Alendronate) - Polyostotic Fibrous Dysplasia | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 40 | 1998-08-24 | 2017-07-02 |
| Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty Testolactone - Polyostotic Fibrous Dysplasia, Precocious Puberty | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 100 | 1982-10-01 | 2008-03-04 |
Fibrous Dysplasia, Polyostotic (7) · Puberty, Precocious (2) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Osteomalacia (1) · Pain (1) · Rickets (1) · Uterine Hemorrhage (1)
Bone Diseases, Developmental (9) · Musculoskeletal Diseases (9) · Osteochondrodysplasias (9) · Bone Diseases (8) · Endocrine System Diseases (2) · Gonadal Disorders (2) · Pathological Conditions, Signs and Symptoms (2) · Avitaminosis (1) · Calcium Metabolism Disorders (1) · Deficiency Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1)
Denosumab (2) · Alendronate (1) · Anastrozole (1) · Fulvestrant (1) · Risedronic Acid (1) · Testolactone (1) · burosumab (1) · tocilizumab (1)
National Institute of Dental and Craniofacial Research (NIDCR) (4) · AstraZeneca (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Hospices Civils de Lyon (1) · Institut National de la Santé Et de la Recherche Médicale, France (1)
United States (6) · France (4) · Germany (3) · Italy (2) · United Kingdom (2) · Belgium (1) · Netherlands (1) · Russia (1)
PMID 22999294, PMID 25033066, PMID 35104665, PMID 36812441, PMID 38378678, PMID 41534675
2005 (1)